1628690-73-2
1628690-73-2 structure
- Name: LY3202626
- Chemical Name: N-{3-[(4aR,7aS)-2-Amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl}-5-methoxy-2-pyrazinecarboxamide
- CAS Number: 1628690-73-2
- Molecular Formula: C22H20F2N8O2S
- Molecular Weight: 498.508
- Catalog: Signaling Pathways Neuronal Signaling Beta-secretase
- Create Date: 2020-01-12 11:08:51
- Modify Date: 2024-10-03 10:12:19
-
LY3202626 is a small molecule non-selective BACE1 inhibitor, causes dose-dependent reductions in CSF and plasma Aβ concentrations, shows potential for the treatment of Alzheimer's disease. Alzheimer Disease Phase 2 Clinical
| Name | N-{3-[(4aR,7aS)-2-Amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl}-5-methoxy-2-pyrazinecarboxamide |
|---|---|
| Synonyms |
2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy-
N-{3-[(4aR,7aS)-2-Amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl}-5-methoxy-2-pyrazinecarboxamide |
| Description | LY3202626 is a small molecule non-selective BACE1 inhibitor, causes dose-dependent reductions in CSF and plasma Aβ concentrations, shows potential for the treatment of Alzheimer's disease. Alzheimer Disease Phase 2 Clinical |
|---|---|
| References | References View Related Products by Target Beta-secretase (BACE) Alzheimer Disease |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H20F2N8O2S |
| Molecular Weight | 498.508 |
| Exact Mass | 498.139801 |
| LogP | 3.08 |
| Index of Refraction | 1.750 |